What is Vera Therapeutics Debt-to-Equity?
Vera Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.44 Mil. Vera Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $51.27 Mil. Vera Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $101.69 Mil.
Vera Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.53.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vera Therapeutics's Debt-to-Equity or its related term are showing as below:
VERA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.24 Max: 0.53
Current: 0.53
During the past 5 years, the highest Debt-to-Equity Ratio of Vera Therapeutics was 0.53. The lowest was 0.00. And the median was 0.24.
Vera Therapeutics Debt-to-Equity Historical Data
The historical data trend for Vera Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vera Therapeutics Debt-to-Equity Chart
|
Vera Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
- |
- |
0.07 |
0.41 |
0.53 |
|
Vera Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
0.41 |
0.20 |
0.21 |
0.24 |
0.53 |
Competitive Comparison of Vera Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Vera Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vera Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vera Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vera Therapeutics's Debt-to-Equity falls into.
Vera Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Vera Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Vera Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vera Therapeutics (Vera Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Executives
| Commodore Capital Lp |
10 percent owner |
444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022 |
| Marshall Fordyce |
director, officer: President and CEO |
C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005 |
| Celia Lin |
officer: Chief Medical Officer |
C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005 |
| Joanne Curley |
officer: Chief Development Officer |
C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080 |
| Sean Grant |
officer: Chief Financial Officer |
C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005 |
| Beth C Seidenberg |
director |
|
| Sofinnova Management X-a, L.l.c. |
10 percent owner |
3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| Sofinnova Venture Partners X, L.p. |
10 percent owner |
3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
| Longitude Capital Partners Iv, Llc |
10 percent owner |
2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
| Longitude Prime Partners, Llc |
10 percent owner |
2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
| Longitude Prime Fund, L.p. |
10 percent owner |
2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
| Patrick G Enright |
director, 10 percent owner |
CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
| Llp Abingworth |
10 percent owner |
38 JERMYN STREET, LONDON X0 SW1Y 6DN |
| Abingworth Bioventures 8 Lp |
10 percent owner |
38 JERMYN STREET, LONDON X0 SW1Y 6DN |
| Carlyle Group Inc. |
10 percent owner |
C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
Vera Therapeutics (Vera Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VERA has been successfully added to your